HMGCR and neoplasm: Taken together, our data indicate that HMGCR inhibition with simvastatin can reverse ferroptosis resistance of immune-edited tumor cells, thereby enhancing the therapeutic efficacy of T-cell based immunotherapy, such as ACT and ICB therapy.